Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

LY3410738

Name: LY3410738: a first-in-class covalent inhibitor of mutant IDH1 in CCA
Uploaded: 2021-01-07T00:00:00Z
Duration: 1 min 52 s
Description: Rachna T. Shroff, MD, University of Arizona Cancer Center, Tucson, AZ, discusses an ongoing Phase I study evaluating LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma (CCA) and other advanced solid tumors. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sorry, no posts matched your criteria.

LY3410738

Cookie settings